nc state health plan glp 1 Why cut access to obesity drugs Wegovy North Carolina State Health Plan

148:1011-1022 [PMC free article: PMC10516173] [PubMed: 37621153] 167

For anyone testing the waters before committing, the makers highlight their trial pathways as a way to reduce uncertainty

Given the 2025 shortage resolutions, a program defaulting everyone to compounded product should be able to explain that choice

A research ethics board approved this study prior to all chart review activities

Although lupus patients were not part of the original clinical trials for GLP-1 RAs, this new data indicates that the drugs could significantly improve outcomes for those battling lupus-related complications

This is partly due to the negative effect of diabetes on the immune system, but its also partly due to the role sugar plays in managing vaginal bacteria